BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Australia's TGA clarifies questions surrounding audits for comparable overseas regulators

March 22, 2019
By Tamra Sami

New Zealand's CuroNZ tests neural regeneration peptides for epilepsy, Lennox-Gastaut

March 20, 2019
By Tamra Sami
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
Read More

Australia's Biomedical Translation Fund launches Respirion, funds work on antibiotic for CF patients

March 20, 2019
By Tamra Sami
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
Read More

Australia's Biomedical Translation Fund launches Respirion, funds work on antibiotic for CF patients

March 19, 2019
By Tamra Sami
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
Read More

Australia to accept conformity assessments from U.K. NBs in no-deal Brexit scenario

March 15, 2019
By Tamra Sami

New Zealand's CuroNZ tests neural regeneration peptides for epilepsy, Lennox-Gastaut

March 14, 2019
By Tamra Sami
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
Read More

Australian smart needle could reduce risk of brain hemorrhage from biopsies

March 12, 2019
By Tamra Sami

New Zealand's Volpara AI algorithms could have massive implications for breast cancer screenings

March 11, 2019
By Tamra Sami

Admedus trialing 3D tissue-engineered heart valve

March 4, 2019
By Tamra Sami

Australia looks to reduce barriers for generic drugs to enter the market

Feb. 26, 2019
By Tamra Sami
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is asking industry stakeholders for feedback on a draft guidance to reform the generic drugs market authorization process.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing